Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer

First Posted Date: 2004-07-21

Last Posted Date: 2008-12-04

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 86

Registration Number: NCT00088088

Locations: 🇺🇸
Cancer Institute Medical Group, Santa Monica, California, United States
🇺🇸
Oncology Hematology Consultants, Sarasota, Florida, United States
🇺🇸
Overton Brooks, VAMC, Shreveport, Louisiana, United States

and more 16 locations

Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: gemcitabine hydrochloride
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2004-07-19

Last Posted Date: 2013-11-26

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 72

Registration Number: NCT00004160

Locations: 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-07-19

Last Posted Date: 2013-06-21

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00003881

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Veterans Affairs Medical Center - Cleveland, Cleveland, Ohio, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

and more 68 locations

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2004-07-19

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00005806

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2004-07-16

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00003877

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2004-07-13

Last Posted Date: 2012-03-06

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 450

Registration Number: NCT00003589

Locations: 🇳🇱
Catharina Ziekenhuis, Eindhoven, Netherlands
🇳🇱
Ziekenhuis de Heel, Zaandam, Netherlands
🇨🇭
Ospedale San Giovanni, Bellinzona, Switzerland

and more 30 locations

17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: tanespimycin
Drug: paclitaxel
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2004-07-12

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00087217

Locations: 🇺🇸
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States

Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2004-07-08

Last Posted Date: 2012-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 33

Registration Number: NCT00003230

Locations: 🇨🇭
Office of Walter Weber-Stadelman, Basel, Switzerland
🇨🇭
University Hospital, Basel, Switzerland
🇨🇭
Kantonspital Aarau, Aarau, Switzerland

and more 6 locations

Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-07-07

Last Posted Date: 2013-12-04

Lead Sponsor: Medical Research Council

Target Recruit Count: 704

Registration Number: NCT00002953

Locations: 🇬🇧
University Birmingham, Birmingham, England, United Kingdom
🇬🇧
Norfolk & Norwich Hospital, Norwich, England, United Kingdom
🇿🇦
Groote Schuur Hospital, Cape Town, Cape Town, South Africa

and more 16 locations

Paclitaxel in Treating Patients With Advanced Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-07-07

Last Posted Date: 2023-06-18

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00002922

Locations: 🇺🇸
Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Chicago (Lakeside), Chicago, Illinois, United States

and more 21 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy